Actio Biosciences Initiates Phase 1b/2 Trial of ABS-1230 for Rare Pediatric Epilepsy
核心洞察
Actio Biosciences (搜索) has launched the KYRON Phase 1b/2 clinical trial of ABS-1230, a precision-designed small molecule inhibitor targeting KCNT1-related epilepsy (搜索), a rare and often fatal pediatric condition.
ABS-1230 has been accepted into the FDA's Rare Disease Evidence Principles process, which facilitates development of therapies for ultra-rare genetic diseases through collaborative regulatory frameworks.
The trial will evaluate safety, tolerability, and efficacy of the oral therapy in children and young adults aged one month to 21 years with KCNT1-related epilepsy (搜索).
Actio Biosciences (搜索) has initiated the KYRON Phase 1b/2 clinical trial of ABS-1230, marking a significant milestone in the development of targeted therapies for KCNT1-related epilepsy (搜索), a rare, severe and often fatal pediatric developmental epileptic encephalopathy (搜索). The San Diego-based clinical-stage biotechnology company announced that ABS-1230, designed as a potent and selective orally available small molecule KCNT1 (搜索) inhibitor, directly addresses the underlying genetic mechanism of this devastating condition.
The investigational therapy has also been accepted into the FDA's Rare Disease Evidence Principles (RDEP) process, a regulatory framework established in September 2025 to facilitate development of therapies for ultra-rare, genetically defined diseases. This acceptance provides a collaborative pathway that may help clarify the route to bringing ABS-1230 to patients with significant unmet medical need.
Clinical Trial Design and Patient Population
The KYRON Phase 1b/2 study will evaluate the safety, tolerability and pharmacokinetics of ABS-1230 administered orally or via feeding tube in children and young adults aged one month through 21 years with KCNT1-related epilepsy (搜索). The trial is structured in three distinct parts:
Part 1 consists of a 12-week open-label single-arm treatment study of ABS-1230, while Part 2 involves a 12-week randomized, double-blind, placebo-controlled study in additional participants. Part 3 offers an optional open-label long-term extension for participants completing either Part 1 or 2.
Initial enrollment will focus on older children and young adults, with progression to younger children and infants determined following evaluation of safety, tolerability and confirmation of appropriate dosing in each age group. The study will also assess the effects of ABS-1230 on seizure activity and neurodevelopmental outcomes.
Promising Safety Profile from Phase 1a
In the Phase 1a healthy volunteer trial, all doses of ABS-1230, including multiple doses of 20 mg, were well tolerated with no serious adverse events reported. This safety data reinforces confidence in the therapy's potential to meaningfully reduce seizure burden in patients with KCNT1-related epilepsy (搜索).
Addressing Critical Unmet Medical Need
KCNT1-related epilepsy (搜索) represents a particularly challenging condition where patients experience frequent treatment-resistant seizures that typically begin in early infancy and are accompanied by profound developmental delays and neurological impairments. General antiepileptic drugs have limited benefit in patients with this genetic epilepsy and are often associated with debilitating side effects.
"For families in this community, including mine, the focus each day is simple and urgent: keeping our children alive. Relentless seizures, medical fragility and profound developmental challenges define daily life," said Justin West, M.D., co-founder and president of the KCNT1 Epilepsy Foundation (搜索). "The start of Actio's KYRON trial represents real progress and renewed hope for families who have waited far too long for a treatment designed specifically for KCNT1-related epilepsy (搜索)."
Precision Medicine Approach
ABS-1230 is designed as a precision-designed inhibitor of the overactive KCNT1 (搜索) potassium ion channel that directly targets the underlying genetic driver of disease. In preclinical studies, ABS-1230 inhibited all tested pathogenic mutations in the KCNT1 gene, indicating potential to treat all patients with KCNT1-related epilepsy (搜索).
"The initiation of the KYRON trial marks a pivotal moment in our mission to bring a potentially disease-modifying, targeted therapy to children living with KCNT1-related epilepsy (搜索) and their families," said David Goldstein, Ph.D., CEO of Actio Biosciences (搜索). "ABS-1230 is an investigational, precision-designed inhibitor of the overactive KCNT1 (搜索) potassium ion channel that directly targets the underlying genetic driver of disease, and our preclinical and Phase 1a data reinforce our confidence in its potential to meaningfully reduce seizure burden."
Regulatory Pathway and Designations
The therapy has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations, in addition to acceptance into the RDEP process. Under the RDEP framework, FDA expects that substantial evidence of effectiveness may generally be established based on one adequate and well-controlled study, including a single-arm trial, together with strong confirmatory evidence supporting the drug's treatment effect.
The RDEP process specifically targets investigative therapies that address genetic defects in very small, rare disease populations facing rapid deterioration in function leading to disability or death, for whom no adequate alternative therapies exist.
Actio has launched a dedicated patient resource at ActioTrials.com to support families seeking information about the KYRON clinical trial, including details about trial eligibility and locations.